Back to top
more

Aquestive Therapeutics (AQST)

(Real Time Quote from BATS)

$3.04 USD

3.04
264,678

-0.16 (-5.00%)

Updated Jul 22, 2024 10:58 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (146 out of 250)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?

Here is how Aquestive Therapeutics (AQST) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.

Aquestive Therapeutics (AQST) Stock Falls Amid Market Uptick: What Investors Need to Know

The latest trading day saw Aquestive Therapeutics (AQST) settling at $1.54, representing a -1.91% change from its previous close.

Aquestive Therapeutics (AQST) Beats Stock Market Upswing: What Investors Need to Know

In the closing of the recent trading day, Aquestive Therapeutics (AQST) stood at $1.43, denoting a +1.42% change from the preceding trading day.

Aquestive Therapeutics (AQST) Stock Sinks As Market Gains: Here's Why

Aquestive Therapeutics (AQST) closed at $1.32 in the latest trading session, marking a -0.75% move from the prior day.

Aquestive Therapeutics (AQST) Stock Moves -0.71%: What You Should Know

In the latest trading session, Aquestive Therapeutics (AQST) closed at $1.39, marking a -0.71% move from the previous day.

Aquestive Therapeutics (AQST) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Aquestive Therapeutics (AQST) closed at $1.52, marking a -0.65% move from the previous day.

Aquestive (AQST) Up on Reaffirming Anaphylm Development Pathway

Aquestive (AQST) stock rises 11.8% as the company intends to begin a pivotal pharmacokinetic study of Anaphylm as an oral epinephrine product candidate in the fourth quarter of 2023.

Aquestive Therapeutics (AQST) Gains As Market Dips: What You Should Know

Aquestive Therapeutics (AQST) closed the most recent trading day at $1.62, moving +0.62% from the previous trading session.

Aquestive Therapeutics (AQST) Flat As Market Gains: What You Should Know

Aquestive Therapeutics (AQST) closed at $1.66 in the latest trading session, marking no change from the prior day.

Aquestive's (AQST) Libervant Accepted for FDA Review, Stock Up

Aquestive (AQST) announces FDA acceptance of a regulatory application seeking approval for Libervant to treat pediatric patients with frequent seizure activity. The stock rises 4.7% in response.

Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 9.09% and 23.06%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Aquestive (AQST) to Report Q2 Earnings: What's in Store?

Aquestive's (AQST) second-quarter 2023 revenues are likely to have been driven by rising licensed product revenues.

Aquestive Therapeutics (AQST) Stock Sinks As Market Gains: What You Should Know

Aquestive Therapeutics (AQST) closed at $1.58 in the latest trading session, marking a -1.25% move from the prior day.

Aquestive Therapeutics (AQST) Outpaces Stock Market Gains: What You Should Know

Aquestive Therapeutics (AQST) closed the most recent trading day at $1.64, moving +1.86% from the previous trading session.

Are Medical Stocks Lagging Aquestive Therapeutics (AQST) This Year?

Here is how Aquestive Therapeutics (AQST) and HCA Healthcare (HCA) have performed compared to their sector so far this year.

Aquestive Therapeutics (AQST) Gains But Lags Market: What You Should Know

Aquestive Therapeutics (AQST) closed at $1.62 in the latest trading session, marking a +0.62% move from the prior day.

Down -31.17% in 4 Weeks, Here's Why Aquestive Therapeutics (AQST) Looks Ripe for a Turnaround

Aquestive Therapeutics (AQST) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Are Medical Stocks Lagging Agios Pharmaceuticals (AGIO) This Year?

Here is how Agios Pharmaceuticals (AGIO) and Aquestive Therapeutics (AQST) have performed compared to their sector so far this year.

Alpine Immune Sciences, Inc. (ALPN) Soars 5.6%: Is Further Upside Left in the Stock?

Alpine Immune Sciences, Inc. (ALPN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Is Anebulo Pharmaceuticals (ANEB) Outperforming Other Medical Stocks This Year?

Here is how Anebulo Pharmaceuticals, Inc. (ANEB) and Aquestive Therapeutics (AQST) have performed compared to their sector so far this year.

Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?

Here is how Aquestive Therapeutics (AQST) and Corvus Pharmaceuticals (CRVS) have performed compared to their sector so far this year.

Are You Looking for a Top Momentum Pick? Why Aquestive Therapeutics (AQST) is a Great Choice

Does Aquestive Therapeutics (AQST) have what it takes to be a top stock pick for momentum investors? Let's find out.

Best Momentum Stocks to Buy for May 9th

AQST, PLTK and WWD made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 9, 2023.

New Strong Buy Stocks for May 9th

SBGI, AQST, PLTK, GTX and LRMR have been added to the Zacks Rank #1 (Strong Buy) List on May 9, 2023

Aquestive Therapeutics (AQST) Tops Q1 Earnings and Revenue Estimates

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 210% and 9.48%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?